Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin
Название протокола
Клинические исследование Muscle Invasive Bladder Cancer: Durvalumab, Tremelimumab, Enfortumab Vedotin, Radical Cystectomy - Реестр клинических исследований
